MetaCap

BeyondSpring (BYSI) vs NewcelX (NCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed BeyondSpring (BYSI) over the past year, losing 22.3% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($14.7 million vs $13.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-82.77%NCEL-22.32%
+57%-16%-89%
Nov 21, 20251 yearNov 20, 2026
BYSI-97.51%NCEL-99.68%
+14%-46%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus NCEL key metrics
MetricBYSINCEL
Share price$0.33$2.54
Market cap$13.66M$14.67M
1-day change-24.49%-5.58%
YTD return-79.75%+33.68%
1-year return-82.77%-22.32%
5-year return-97.70%-99.65%
P/E ratio (TTM)—4.88
EPS (TTM)$-0.20$0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-1.01M$-8.30M
52-week high$2.44$5.12
52-week low$0.299$1.83
Distance from 52-week high-86.48%-50.39%
Analyst consensus—none
Avg. price target upside—+805.51%
Average volume261.79K13.34K
Shares outstanding41.41M5.78M
Employees449
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed BYSI by 60.4 percentage points over the past year.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

BYSI vs NCEL FAQ

Which is bigger, BeyondSpring or NewcelX?

NewcelX (NCEL) is larger, with a market capitalization of $14.67M compared with $13.66M for BeyondSpring (BYSI).

Which stock has performed better over the past year, BYSI or NCEL?

NCEL returned -22.32% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.

Are BeyondSpring and NewcelX in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons